Cargando…
Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection
Globally, it is estimated that one-quarter of the world’s population is latently infected with Mycobacterium tuberculosis (Mtb), also known as latent tuberculosis infection (LTBI). Recently, this condition has been referred to as tuberculosis infection (TBI), considering the dynamic spectrum of the...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960903/ https://www.ncbi.nlm.nih.gov/pubmed/36828505 http://dx.doi.org/10.3390/tropicalmed8020089 |
_version_ | 1784895623921664000 |
---|---|
author | Chin, Kai Ling Anibarro, Luis Sarmiento, Maria E. Acosta, Armando |
author_facet | Chin, Kai Ling Anibarro, Luis Sarmiento, Maria E. Acosta, Armando |
author_sort | Chin, Kai Ling |
collection | PubMed |
description | Globally, it is estimated that one-quarter of the world’s population is latently infected with Mycobacterium tuberculosis (Mtb), also known as latent tuberculosis infection (LTBI). Recently, this condition has been referred to as tuberculosis infection (TBI), considering the dynamic spectrum of the infection, as 5–10% of the latently infected population will develop active TB (ATB). The chances of TBI development increase due to close contact with index TB patients. The emergence of multidrug-resistant TB (MDR-TB) and the risk of development of latent MDR-TB has further complicated the situation. Detection of TBI is challenging as the infected individual does not present symptoms. Currently, there is no gold standard for TBI diagnosis, and the only screening tests are tuberculin skin test (TST) and interferon gamma release assays (IGRAs). However, these tests have several limitations, including the inability to differentiate between ATB and TBI, false-positive results in BCG-vaccinated individuals (only for TST), false-negative results in children, elderly, and immunocompromised patients, and the inability to predict the progression to ATB, among others. Thus, new host markers and Mtb-specific antigens are being tested to develop new diagnostic methods. Besides screening, TBI therapy is a key intervention for TB control. However, the long-course treatment and associated side effects result in non-adherence to the treatment. Additionally, the latent MDR strains are not susceptible to the current TBI treatments, which add an additional challenge. This review discusses the current situation of TBI, as well as the challenges and efforts involved in its control. |
format | Online Article Text |
id | pubmed-9960903 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99609032023-02-26 Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection Chin, Kai Ling Anibarro, Luis Sarmiento, Maria E. Acosta, Armando Trop Med Infect Dis Review Globally, it is estimated that one-quarter of the world’s population is latently infected with Mycobacterium tuberculosis (Mtb), also known as latent tuberculosis infection (LTBI). Recently, this condition has been referred to as tuberculosis infection (TBI), considering the dynamic spectrum of the infection, as 5–10% of the latently infected population will develop active TB (ATB). The chances of TBI development increase due to close contact with index TB patients. The emergence of multidrug-resistant TB (MDR-TB) and the risk of development of latent MDR-TB has further complicated the situation. Detection of TBI is challenging as the infected individual does not present symptoms. Currently, there is no gold standard for TBI diagnosis, and the only screening tests are tuberculin skin test (TST) and interferon gamma release assays (IGRAs). However, these tests have several limitations, including the inability to differentiate between ATB and TBI, false-positive results in BCG-vaccinated individuals (only for TST), false-negative results in children, elderly, and immunocompromised patients, and the inability to predict the progression to ATB, among others. Thus, new host markers and Mtb-specific antigens are being tested to develop new diagnostic methods. Besides screening, TBI therapy is a key intervention for TB control. However, the long-course treatment and associated side effects result in non-adherence to the treatment. Additionally, the latent MDR strains are not susceptible to the current TBI treatments, which add an additional challenge. This review discusses the current situation of TBI, as well as the challenges and efforts involved in its control. MDPI 2023-01-28 /pmc/articles/PMC9960903/ /pubmed/36828505 http://dx.doi.org/10.3390/tropicalmed8020089 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Chin, Kai Ling Anibarro, Luis Sarmiento, Maria E. Acosta, Armando Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection |
title | Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection |
title_full | Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection |
title_fullStr | Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection |
title_full_unstemmed | Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection |
title_short | Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection |
title_sort | challenges and the way forward in diagnosis and treatment of tuberculosis infection |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960903/ https://www.ncbi.nlm.nih.gov/pubmed/36828505 http://dx.doi.org/10.3390/tropicalmed8020089 |
work_keys_str_mv | AT chinkailing challengesandthewayforwardindiagnosisandtreatmentoftuberculosisinfection AT anibarroluis challengesandthewayforwardindiagnosisandtreatmentoftuberculosisinfection AT sarmientomariae challengesandthewayforwardindiagnosisandtreatmentoftuberculosisinfection AT acostaarmando challengesandthewayforwardindiagnosisandtreatmentoftuberculosisinfection |